SCHEMBL3123334

SCHEMBL3123334

[CH2]C1CC=CC=N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9830453 0.69
SCHEMBL4480868 0.67
SCHEMBL1679515 0.67
SCHEMBL13674570 0.67
SCHEMBL14445008 0.67
SCHEMBL8266084 0.67
SCHEMBL19202494 0.67
SCHEMBL7265383 0.67
SCHEMBL3601925 0.67
SCHEMBL20389168 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022256299-A1 7-MORPHOLINO-5-(3-PHENYL-1 H-PYRAZOL-1 -YL)-FURO[3,2-B]PYRIDINE DERIVATIVES AND SIMILAR COMPOUNDS AS PIKFYVE KINASE INHIBITORS FOR THE TREATMENT OF E.G. AMYOTROPHIC LATERAL SCLEROSIS (ALS) Verge Analytics, Inc. (US) 2022-12-08 WO claimed
US-20070232607-A1 Quinazoline Derivatives as Erbb Receptor Tyrosine kinases BRADBURY ROBERT H 2007-10-04 US claimed
JP-2007506716-A 2007-03-22 JP claimed
EP-1756088-A1 QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES AstraZeneca AB (SE) 2007-02-28 EP claimed
US-20070043010-A1 Quinazoline derivatives ASTRAZENECA UK LIMITED (GB) 2007-02-22 US claimed
EP-1670786-A1 QUINAZOLINE DERIVATIVES Astrazeneca AB (SE) 2006-06-21 EP claimed
WO-2005118572-A1 QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES ASTRAZENECA AB (SE) 2005-12-15 WO claimed
WO-2005030757-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-04-07 WO claimed
EP-0201459-A1 Acylaminomethyl-penem compounds, their preparation and pharmaceutical formulations containing them CIBA-GEIGY AG (CH) 1986-11-12 EP claimed
EP-3533797-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2023-12-20 EP disclosed
WO-2022256300-A1 FUSED BICYCLIC HETEROCYCLIC COMPOUNDS AND USES THEREOF Verge Analytics, Inc. (US) 2022-12-08 WO disclosed
WO-2022256299-A1 7-MORPHOLINO-5-(3-PHENYL-1 H-PYRAZOL-1 -YL)-FURO[3,2-B]PYRIDINE DERIVATIVES AND SIMILAR COMPOUNDS AS PIKFYVE KINASE INHIBITORS FOR THE TREATMENT OF E.G. AMYOTROPHIC LATERAL SCLEROSIS (ALS) Verge Analytics, Inc. (US) 2022-12-08 WO disclosed
EP-3533797-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2019-09-04 EP disclosed
EP-2540728-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-04-10 EP disclosed
EP-0215739-B1 SYNTHESIS OF BETA-LACTAM COMPOUNDS CIBA-GEIGY AG (CH) 1993-09-01 EP disclosed
US-5215997-A Synthesis of beta-lactam compounds CIBA-GEIGY CORPORATION (US) 1993-06-01 US disclosed
US-5153315-A Penicilllin deriviatives CIBA-GEIGY CORPORATION (US) 1992-10-06 US disclosed
US-4962196-A (3S, 4R)-3,4-trans-disubstituted azetidin-2-one intermediates CIBA-GEIGY CORPORATION (US) 1990-10-09 US disclosed
EP-0215739-A1 Synthesis of beta-lactam compounds CIBA-GEIGY AG (CH) 1987-03-25 EP disclosed
EP-0201459-A1 Acylaminomethyl-penem compounds, their preparation and pharmaceutical formulations containing them CIBA-GEIGY AG (CH) 1986-11-12 EP disclosed